Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
SGLT2 Inhibitors and Cardiovascular Outcomes Trials: 4 Questions
Refresh your memory on findings from the EMPA-REG OUTCOME, CANVAS, CREDENCE, and DECLARE-TIMI cardiovascular outcomes trials on SGLT2 inhibitors.
Cardiovascular (CV) outcomes trials have generally shown that sodium–glucose cotransporter 2 inhibitors (SGLT2i) decrease CV risk in patients with type 2 diabetes mellitus (T2DM). Major CV outcomes randomized controlled trials (RCTs) for this class of drugs include:
- EMPA-REG OUTCOME: 7020 participants with T2DM at high CV risk randomized to empagliflozin or placebo; median follow-up of 3.1 years
- DECLARE-TIMI: 17 160 participants with T2DM at high CV risk randomized to dapagliflozin or placebo; median follow-up of 4.2 years
- CREDENCE: 4401 participants with T2DM and chronic kidney disease randomized to canagliflozin or placebo; median follow-up of 2.62 years
- CANVAS: 10 142 participants with T2DM at high CV risk randomized to canagliflozin or placebo; median follow-up of 3.6 years
Test your knowledge on the 4 major CV outcomes RCTs for SGLT2i with the 8-question quiz below.
1. Which trial failed to find significantly decreased 3-point major adverse CV events (MACE) in patients with T2DM?
A. EMPA-REG OUTCOME
B. DECLARE-TIMI
C. CANVAS
D. CREDENCE
Related Videos
